Atypical haemolytic uraemic syndrome in a patient with sickle cell disease, successfully treated with eculizumab

British Journal of Haematology

Volumn 175, Issue 4, 2016, Pages 744-747

  Chonat, Satheesh ^a   Chandrakasan, Shanmuganathan ^a   Kalinyak, Karen Ann ^a   Ingala, David ^a   Gruppo, Ralph ^a   Kalfa, Theodosia A ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

atypical haemolytic uraemic syndrome; complement mutations; eculizumab; sickle cell disease; thrombotic microangiopathy

Indexed keywords

ECULIZUMAB; MONOCLONAL ANTIBODY;

COMPLICATION; HEMOLYTIC UREMIC SYNDROME; HUMAN; PATHOLOGY; SICKLE CELL ANEMIA;

ANEMIA, SICKLE CELL; ANTIBODIES, MONOCLONAL, HUMANIZED; ATYPICAL HEMOLYTIC UREMIC SYNDROME; HUMANS;

EID: 84983095493     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13884     Document Type: Letter

References (10)

1. Bolanos-Meade, J., Keung, Y.K., Lopez-Arvizu, C., Florendo, R. & Cobos, E. (1999) Thrombotic thrombocytopenic purpura in a patient with sickle cell crisis. Annals of Hematology, 78, 558–559.
2. Cataland, S.R. & Wu, H.M. (2014) How I treat: the clinical differentiation and initial treatment of adult patients with atypical hemolytic uremic syndrome. Blood, 123, 2478–2484.
3. Chen, J., Hobbs, W.E., Le, J., Lenting, P.J., de Groot, P.G. & Lopez, J.A. (2011) The rate of hemolysis in sickle cell disease correlates with the quantity of active von Willebrand factor in the plasma. Blood, 117, 3680–3683.
4. Frimat, M., Tabarin, F., Dimitrov, J.D., Poitou, C., Halbwachs-Mecarelli, L., Fremeaux-Bacchi, V. & Roumenina, L.T. (2013) Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome. Blood, 122, 282–292.
5. Lee, H.E., Marder, V.J., Logan, L.J., Friedman, S. & Miller, B.J. (2003) Life-threatening thrombotic thrombocytopenic purpura (TTP) in a patient with sickle cell-hemoglobin C disease. Annals of Hematology, 82, 702–704.
6. Maga, T.K., Nishimura, C.J., Weaver, A.E., Frees, K.L. & Smith, R.J. (2010) Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome. Human Mutation, 31, E1445–E1460.
7. Roumenina, L.T., Loirat, C., Dragon-Durey, M.A., Halbwachs-Mecarelli, L., Sautes-Fridman, C. & Fremeaux-Bacchi, V. (2011) Alternative complement pathway assessment in patients with atypical HUS. Journal of Immunological Methods, 365, 8–26.
8. Shome, D.K., Ramadorai, P., Al-Ajmi, A., Ali, F. & Malik, N. (2013) Thrombotic microangiopathy in sickle cell disease crisis. Annals of Hematology, 92, 509–515.
9. Tsai, H.M. (2014) A mechanistic approach to the diagnosis and management of atypical hemolytic uremic syndrome. Transfusion Medicine Reviews, 28, 187–197.
10. Wang, R.H., Phillips, Jr, G., Medof, M.E. & Mold, C. (1993) Activation of the alternative complement pathway by exposure of phosphatidylethanolamine and phosphatidylserine on erythrocytes from sickle cell disease patients. Journal of Clinical Investigation, 92, 1326–1335.